AbbVie (ABBV) director Alpern adds stock equivalent units via fees

Rhea-AI Filing Summary

AbbVie Inc. director Robert J. Alpern reported a routine compensation-related transaction. On 12/31/2025, he acquired 34 stock equivalent units tied to AbbVie common stock at $228.49 per unit, bringing his total holdings of these derivative securities to 10,257 stock equivalent units.

According to the disclosure, these units represent director fees credited to stock equivalent unit accounts under grantor trusts established at Abbott Laboratories and AbbVie. The units are paid out in cash, generally at age 65 or upon retirement from each company’s board, and earn the same return as if the fees were invested in AbbVie stock. The reported balance also reflects units acquired through a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alpern Robert J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$228.49	12/31/2025		A		34		(1)	(1)	Common Stock	34	$228.49	10,257(2)	D

Explanation of Responses:

1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) director Robert J. Alpern report?

Robert J. Alpern reported acquiring 34 stock equivalent units tied to AbbVie common stock on 12/31/2025 at a price of $228.49 per unit, as part of his director compensation.

How many AbbVie stock equivalent units does Robert J. Alpern now beneficially own?

After the reported transaction, Robert J. Alpern beneficially owns 10,257 stock equivalent units linked to AbbVie common stock.

What are the stock equivalent units reported in this AbbVie (ABBV) Form 4?

The stock equivalent units are director fees credited to stock equivalent unit accounts under grantor trusts at Abbott Laboratories and AbbVie. They earn the same return as if the fees were invested in AbbVie stock and are ultimately paid out in cash.

When will Robert J. Alpern’s AbbVie stock equivalent units be paid out?

The filing states that stock equivalent units in each account will be paid, in cash, generally at age 65 or upon retirement from the respective company’s board.

Does the AbbVie (ABBV) Form 4 indicate dividend reinvestment for these units?

Yes. The disclosure notes that the reported balance of 10,257 stock equivalent units includes units acquired pursuant to a dividend reinvestment feature.

Is Robert J. Alpern considered a director or officer of AbbVie (ABBV) in this filing?

The form identifies Robert J. Alpern’s relationship to AbbVie as a Director. No officer title or 10% ownership status is indicated.